PP2A与进展期胃癌患者预后关系的生存分析-东南大学学报医学版

PP2A与进展期胃癌患者预后关系的生存分析

单位：1. 邯郸市中心医院肿瘤二科, 河北邯郸 056001;
2. 邯郸市中心医院手术室, 河北邯郸 056001;
3. 邯郸市人民医院外二科, 河北邯郸 056001;
4. 邯郸市中心医院神外二科, 河北邯郸 056001;
5. 邯郸市中心医院普外七科, 河北邯郸 056001

关键词：蛋白磷酸酯酶2A 进展期胃癌生存分析

分类号：R735.2

出版年·卷·期（页码）：2023·42·第四期（512-519）

摘要：

目的:探讨蛋白磷酸酯酶2A(PP2A)与进展期胃癌患者预后的关系。方法: 选取2016年1月至2017年9月在邯郸市中心医院就诊的95例进展期胃癌患者作为研究对象,临床分期为Ⅱ~Ⅲ期,均接受根治性手术治疗。分析PP2A与进展期胃癌患者术后肿瘤复发转移和死亡的相关性,绘制PP2A预测进展期胃癌患者根治术后5年内肿瘤复发转移和死亡的受试者工作特征(ROC)曲线和决策曲线,以PP2A的两个最佳诊断截点将所有患者分为A、B组及C、D组,Kaplan-Meier生存分析比较两组患者根治术后5年无病生存率和总生存率。结果: 多因素Cox回归分析结果显示,血管侵犯、侵犯深度以及PP2A为影响进展期胃癌患者根治术后5年内肿瘤复发转移和死亡的独立预测因素(P<0.05)。ROC曲线分析结果显示,血管侵犯、侵犯深度以及PP2A预测进展期胃癌患者根治术后5年内肿瘤复发转移的曲线下面积(AUC)分别为0.782(95%CI:0.712~0.834)、0.854(95%CI:0.791~0.913)以及0.754(95%CI:0.713~0.792),PP2A的最佳诊断截点为4.35 pg·ml^-1,三者联合预测的AUC为0.963(95%CI:0.911~0.987);血管侵犯、侵犯深度以及PP2A预测进展期胃癌患者根治术后5年内死亡的AUC分别为0.756(95%CI:0.714~0.795)、0.869(95%CI:0.816~0.907)以及0.784(95%CI:0.732~0.839),PP2A的最佳诊断截点为4.41 pg·ml^-1,三者联合预测的AUC为0.957(95%CI:0.921~0.984)。Kaplan-Meier生存分析结果显示,A组进展期胃癌患者根治术后1、3、5年无病生存率明显高于B组(71.4%、45.6%、32.5%vs. 52.3%、19.7%、17.2%,P<0.05),C组进展期胃癌患者根治术后1、3、5年总生存率明显高于D组(91.3%、83.7%、64.6%vs. 81.4%、54.5%、43.8%,P<0.05)。决策曲线分析结果显示,在大多数合理阈值概率范围内,血管侵犯、侵犯深度以及PP2A预测进展期胃癌患者根治术后5年内肿瘤复发转移和死亡均具有良好的净收益率。结论: 血清PP2A表达水平较低的进展期胃癌患者,其根治术后肿瘤复发转移风险高,无病生存率和总生存率低。

Objective: To investigate the relationship between protein phosphatase 2A(PP2A) and the prognosis of patients with advanced gastric cancer. Methods: 95 patients with advanced gastric cancer who were treated in our hospital from January 2016 to September 2017 were selected as the study objects. The clinical stages were Phase II to III, and all patients received radical surgery. The correlation between PP2A and tumor recurrence, metastasis and death of patients with advanced gastric cancer after radical surgery was analyzed, and the ROC curve and decision curve of PP2A predicting tumor recurrence, metastasis and death of patients with advanced gastric cancer within 5 years after radical surgery were drawn.All patients were divided into group A and group B, group C and group D according to the best diagnostic cut-off point of PP2A. Kaplan Meier survival analysis was used to compare the 5-year disease-free survival rate and overall survival rate of patients in the two groups after radical surgery. Results: Multivariate Cox regression analysis showed that vascular invasion, invasion depth and PP2A were independent predictors of tumor recurrence, metastasis and death in patients with advanced gastric cancer within 5 years after radical surgery(P<0.05). The ROC analysis results showed that the area under the curve(AUC) of vascular invasion, depth of invasion and PP2A predicting tumor recurrence and metastasis in patients with advanced gastric cancer within 5 years after radical surgery were 0.782(95%CI:0.712-0.834), 0.854(95%CI:0.791-0.913) and 0.754(95%CI:0.713-0.792) respectively. The best diagnostic cutoff point of PP2A was 4.35 pg·mL^-1. The AUC predicted by the three methods was 0.963(95%CI:0.911-0.987). The AUC of vascular invasion, depth of invasion, and PP2A predicting the death within 5 years after radical surgery in patients with advanced gastric cancer were 0.756(95%CI:0.714-0.795), 0.869(95%CI:0.816-0.907), and 0.784(95%CI:0.732-0.839), respectively. The best cutoff point for diagnosis of PP2A was 4.41 pg·ml^-1. The AUC predicted by the three methods was 0.957(95%CI:0.921-0.984).Kaplan-Meier survival analysis showed that the 1-year, 3-year and 5-year disease-free survival rate of patients with advanced gastric cancer in group A was significantly higher than that in group B(71.4%, 45.6%, 32.5% vs. 52.3%, 19.7%, 17.2%, P<0.05), and the 1-year, 3-year and 5-year overall survival rate of the patients with advanced gastric cancer in group C was significantly higher than that in group D(91.3%, 83.7%, 64.6% vs. 81.4%, 54.5%, 43.8%, P<0.05). The results of decision curve analysis showed that, within the most reasonable threshold probabilities, vascular invasion, invasion depth and PP2A predicted tumor recurrence, metastasis and death in patients with advanced gastric cancer within 5 years after radical surgery had good net gain. Conclusion: Patients with advanced gastric cancer with low serum PP2A expression level have a high risk of tumor recurrence and metastasis after radical surgery, and have a low disease-free survival rate and overall survival rate.

参考文献：

[1] 冯青,龙渡,温燕,等.腹腔镜对比开腹手术治疗新辅助化疗后进展期胃癌近期疗效的Meta分析[J].中华消化外科杂志,2021,20(9):1011-1017.
[2] TAN Z.Recent advances in the surgical treatment of advanced gastric cancer:a review[J].Med Sci Monit,2019,25(5):3537-3541.
[3] 杨海棠,杨凯歌,杨磊.腹腔镜辅助D2式胃癌根治术治疗老年进展期胃癌临床观察[J].中华实用诊断与治疗杂志,2019,33(5):478-479.
[4] SIEBENHüNER A R,DE DOSSO S,HELBLING D,et al.Advanced gastric cancer:current treatment landscape and a future outlook for sequential and personalized guide:swiss expert statement article[J].Oncol Res Treat,2021,44(9):485-494.
[5] MIZUKAMI T,PIAO Y.Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer[J].Future Oncol,2021,17(23):3101-3109.
[6] 薛守貌.PP2A、CA125、HE4诊断宫颈癌的效果分析[J].标记免疫分析与临床,2022,29(4):652-656.
[7] 崔耀夫,董永红.进展期胃癌腹主动脉旁淋巴结清扫对患者生存预后的影响[J].中华肿瘤防治杂志,2020,21(1):9491-9496.
[8] 王玮,张锡山,贾海峰,等.腹腔镜全胃切除胃癌根治术对进展期胃癌患者预后及术后并发症发生率的影响[J].中国全科医学,2021,24(2):35-37.
[9] 曹晋,高立科,薛栋.CIP2A与肿瘤的研究进展[J].华南国防医学杂志,2020,34(4):288-291.
[10] DZULKO M,PONS M,HENKE A,et al.The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation[J].Biochim Biophys Acta Rev Cancer,2020,1874(2):188453.
[11] 杨成雷,黄燊,莫来铭,等.肝癌细胞蛋白磷酸酶2A催化亚基在过氧化氢和黄曲霉毒素B1诱导急慢性肝癌细胞损伤模型中的表达及其对肝癌细胞的影响[J].临床肝胆病杂志,2019,35(12):2730-2735.
[12] VERBINNEN I,VANEYNDE P,REYNHOUT S,et al.Protein phosphatase 2A(PP2A) mutations in brain function,development,and neurologic disease[J].Biochem Soc Trans,2021,49(4):1567-1588.
[13] 陈慧娟,王培晓,张庆.PPP2R3A基因与肿瘤的相关性研究进展[J].浙江医学,2019,41(8):845-847.
[14] MÁTHÉ C,MHAMVAS M,FREYTAG C,et al.The protein phosphatase PP2A plays multiple roles in plant development by regulation of vesicle traffic-facts and questions[J].Int J Mol Sci,2021,22(2):975.
[15] 郑红云,申复进,童永清,等.蛋白磷酸酯酶2A通过MAPK信号通路抑制宫颈癌细胞侵袭[J].微循环学杂志,2019,29(1):1-6.
[16] LU Z,ZHU X,YE Y,et al.PP2A protects podocytes against adriamycin-induced injury and epithelial-to-mesenchymal transition via suppressing JIP4/p38-MAPK pathway[J].Cytotechnology,2021,73(5):697-713.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录